At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses new data that support earlier treatment of patients with mantle cell lymphoma (MCL), including the results of an investigation of a bortezomib-based regimen as frontline therapy for patients with newly diagnosed MCL.
